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Phase I of the Surveillance for Enteric Fever in Asia Project
(SEAP): An Overview and Lessons Learned
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Alex Freeman,1,b Mohammad Tahir Yousafzai,5 and Denise Garrett1
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and Geographic Medicine, Stanford University, California; 4Child Health Research Foundation, Department of Microbiology, Dhaka Shishu (Children) Hospital, Bangladesh;
5Department of Pediatrics and Child Health, Aga Khan University, Karachi, Pakistan; and 6Translational Health Science and Technology Institute, Faridabad, India

Enteric fever, a preventable illness caused by the organisms
Salmonella enterica subspecies enterica serovar Typhi or serovar
Paratyphi, is estimated to cause >15 million illnesses and nearly
153 000 deaths worldwide annually [1, 2]. These organisms are
transmitted through food and water contaminated with fecal
matter, and their control ultimately depends on access to potable water, as well as safely managed sanitation and hygienic
practices in homes and in food production. Vaccines that protect against typhoid fever have been available for many years,
and in March 2018, the World Health Organization (WHO)
recommended the use of a newly prequalified typhoid conjugate vaccine (TCV) for typhoid fever prevention in countries of
endemicity [3]. Compared with the 2 previously available vaccines, TCV provides longer-lasting protection, requires fewer
doses, and is additionally suitable for children aged 6 months to
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<2 years, allowing delivery through routine childhood immunization programs [3–5]. Furthermore, the TCV was included in
the 2019–2020 funding window of Gavi, the Vaccine Alliance
[6]. To deliver the TCV to susceptible populations, it requires
the support of country governments in many low- and middle-income countries, as well as other stakeholders, such as
Gavi, the Vaccine Alliance. However, the absence of credible estimates of the burden of disease has made it difficult to
provide policymakers with accurate estimates of the cost and
potential impact of targeted interventions for prevention and
control of enteric fever, including TCV.
One contributing factor to uncertainty about the burden of
disease is the lack of reliable diagnostic testing. The most consistently valid method for laboratory diagnosis is blood culture,
estimated to be only 61% sensitive [7] in a recent meta-analysis,
and may be dependent on sample volume [8]. In many low- and
middle-income countries, blood culture is also largely unavailable, particularly in rural areas. Additionally, the widespread
use of antibiotics to treat typhoid empirically may reduce the
sensitivity of blood culture and further reduce estimates of disease burden; in Nepal, 35% of participants had taken antibiotics
prior to seeking healthcare at the study hospitals [9].
Over the last 2 decades, several surveillance studies have
attempted to characterize the burden of enteric fever, including the Diseases of the Most Impoverished Program and
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Objective. The objective of Phase I of the Surveillance for Enteric Fever in Asia Project (SEAP), a multiphase surveillance study
characterizing the burden of disease in South Asia, was to inform data collection for prospective surveillance and to capture clinical
aspects of disease.
Methods. Through a retrospective record review conducted at hospitals in Bangladesh, India, Nepal, and Pakistan, we examined
laboratory and clinical records to assess the culture positivity rate for Salmonella Typhi and Salmonella Paratyphi, age and sex distribution, and antimicrobial susceptability in each country.
Results. Of all blood cultures performed in Bangladesh, India, Nepal, and Pakistan, 1.5%, 0.43%, 2%, and 1.49%, respectively,
were positive for S. Typhi and 0.24%, 0.1%, 0.5%, and 0.67%, respectively, were positive for S. Paratyphi. A higher proportion of
laboratory-confirmed infections in Bangladesh and Pakistan were aged ≤5 years, while India and Nepal had a higher proportion of participants aged 15–25 years. In all countries, the sex of the majority of participants was male. The majority of isolates
in all countries were resistant to fluoroquinolones, with a high proportion also resistant to ampicillin, chloramphenicol, and
trimethoprim-sulfamethoxazole.
Discussion. Enteric fever remains endemic in South Asia. Data generated by this study can help inform strategies for implementation and evaluation of prevention and control measures.
Keywords. Typhoid; paratyphoid; enteric fever; Salmonella; South Asia; antimicrobial resistance.

METHODS

Based on the available data in the literature on the geographic
burden of enteric fever, we chose Bangladesh, India, Nepal, and
Pakistan as potential country sites.
Study Site Selection

We conducted a standard assessment of existing hospitals,
health clinics, and laboratories in the area to determine possible study sites. Key variables in the health facility assessment were as follows: (1) existing evidence on the prevalence
of enteric fever; (2) a population that is representative of the
overall demographic and socioeconomic characteristics of
the surrounding population; (3) a strong laboratory capacity
and inpatient (medical and surgical) and outpatient facilities;
(4) a location geographically close to the population served
by the study hospital; (5) the availability of population-based
sociodemographic indicators from reliable sources (eg, bureau
of statistics of the city/district/national level or demographic
health surveys) or the ability to obtain a geographically representative sample, which will allow extrapolation of population
size and demographic characteristics; and (6) a willingness

and commitment to conduct the study on the basis of agreed
upon aims and objectives. Based on this assessment, we chose
several sites in each country, specified below, for inclusion in
the study.
Bangladesh

Two sites were selected in Bangladesh: Dhaka Shishu Hospital, a
640-bed tertiary-care hospital, and Shishu Sasthya Foundation
Hospital, a 200-bed hospital providing primary care only. Both
serve a catchment area of 3.4 million people and are the 2 largest
pediatric hospitals in Dhaka (serving patients aged <18 years).
Owing to proximity, both hospitals are within the same catchment area, in an urban and peri-urban setting. Both hospitals are also sentinel sites in the WHO-coordinated Invasive
Bacterial Vaccine-Preventable Disease surveillance network,
which captures information electronically on hospitalized
patients with suspected or laboratory-confirmed pneumonia,
sepsis, and meningitis. The hospitals were able to use this surveillance network to create a platform to capture enteric fever
cases, which facilitated data collection for Phase I.
India

Five sites were selected in India: the Postgraduate Institute of Medical
Sciences, a mixed public-private tertiary hospital in Chandigarh
with 1960 beds; Medanta Hospital, a private tertiary hospital in
Gurugram (previously known as Gurgaon), Haryana, with 1250
beds; Christian Medical College, a private tertiary hospital in
Vellore, Tamil Nadu, with 2800 beds; Apollo Gleneagles Hospital,
a private tertiary hospital in Kolkata, West Bengal, with 750 beds;
and Kasturba Medical College – Manipal University Hospital, a
private tertiary hospital in Manipal, Karnataka, with around 2000
beds. All sites serve urban populations, except Kasturba Medical
College, which serves a peri-urban population.
Nepal

Sites were chosen because of a prospective enteric fever surveillance study already in place [9], which facilitated data collection.
The 4 selected sites were: Bayalpata Hospital, a 15-bed hospital
serving a rural population in Achlam; Damauli Hospital, a district hospital serving the town of Vyas, which has a population
of 43 000; Kirnetar Health Center, a clinic in rural Dolakha; and
Dhulikhel Hospital in Kavrepalanchowk, serving a peri-urban
population in the greater Kathmandu Valley and with catchment area of approximately 330 000 people.
Pakistan

Three sites in Pakistan were selected, consisting of the 3 hospitals in the Aga Khan University Hospital network: Aga Khan
University Hospital, a 700-bed tertiary care hospital in Karachi;
Aga Khan Hospital for Women and Children, a 48-bed secondary care hospital in Karachi; and Aga Khan Hospital Hyderabad,
an 87-bed secondary care hospital in Hyderabad. Both Aga
Khan Hospital for Women and Children and Aga Khan Hospital
Enteric Fever Surveillance in Asia • JID 2018:218 (Suppl 4) • S189
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the Typhoid Fever Surveillance in Africa Program [10, 11].
While these studies were among the first prospective, population-based studies that estimated the incidence of enteric fever
in Asia and sub-Saharan Africa, they have left several knowledge gaps, including the incidence of specific complications
and the spectrum of disease and severity. Data on the cost of
illness and the geographic spread of strains, including antimicrobial-resistant ones, are also limited. Since these studies, the
Bill and Melinda Gates Foundation has invested in several new
surveillance studies, including the Severe Typhoid in Africa
project and the Surveillance for Enteric Fever in Asia Project
(SEAP). SEAP is a multiphase enteric fever surveillance study
designed to fill knowledge gaps about the burden of disease
in Bangladesh, India, Nepal, and Pakistan. With the ability to
characterize the burden of enteric fever in 3 major cities and 1
peri-urban area within the selected countries, results from this
project will be able to help inform the use of TCVs and other
typhoid prevention and control efforts.
The project has 2 phases: Phase I, a retrospective record
review, and Phase II, a prospective study with defined enrollment criteria, including specific case definitions. Phase I had 3
objectives: (1) identify site hospitals in selected countries where
enteric fever is endemic, to assess the burden of disease through
record review and inform data collection for Phase II surveillance; (2) ensure that the hospital had capacity to participate in
Phase II surveillance; and (3) map cases geographically to confirm the feasibility of creating a well-defined catchment area for
each hospital in which the incidence of enteric disease can be
estimated during Phase II surveillance. This article will present
the results of the first objective.

Hyderabad only provide care for women and children. These
hospitals cover a catchment area of 3 million people.
Study Period, Data Sources, and Case Definitions

After site selection was completed, we conducted a retrospective
review of data available on enteric fever from the selected hospitals, including suspected cases and blood culture–confirmed S.
Typhi and S. Paratyphi infection. A minimum of 2 years of data
were collected to assess any seasonal variation at the selected
sites. Specific methods for the sites, including case definitions,
study periods, and data sources, are described in Table 1.

information, including demographic characteristics, treatments,
investigations, clinical manifestations, and patient outcomes.
Data were abstracted using standard instruments and entered
electronically for analysis, which was performed at the country level. Differences in sex and age distributions were analyzed
using Wilcoxon rank sum tests and differences in proportions.
Blood culture positivity rates and antimicrobial resistance patterns were descriptively reviewed. More details about the analyses performed are available in the country-specific articles
published in this supplement [9, 12–14].

Data Collection and Analysis

Laboratory Data Collection

For each month of data collection, the following information
was obtained from laboratories: the number of blood cultures
performed, the number of blood cultures positive for S. Typhi
and S. Paratyphi, and any available patient-level demographic
information, such as age, sex, neighborhood of residence, and
specimen collection date. For the retrospective phase, patient
address was only collected up to the smallest administrative
unit, to map the catchment area. For Bangladesh and Nepal,
data were extracted retrospectively from prospective studies
already in place.
Inpatient Department Data Collection

Using hospital record numbers and where available, study staff
obtained charts of hospitalized participants with laboratory-confirmed S. Typhi or S. Paratyphi infection and abstracted clinical

The study protocols were reviewed and approved by the Centers
for Disease Control and Prevention (Atlanta, GA); institutional ethics committees at Translational Health Science and
Technology Institute (Faridabad, India), the Postgraduate
Institute of Medical Sciences (Chandigargh, India), Medanta
Hospital (Gurugram, India), Apollo Gleneagles Hospital
(Kolkata, India), Kasturba Medical College – Manipal University
Hospital (Manipal, India); the Institutional Review Board at
Christian Medical College (Vellore, India); the Institutional
Review Board for Human Subjects Research of the Nepal
Health Research Council (Kathmandu, Nepal); the Kathmandu
University School of Medical Sciences Institutional Review
Committee (Dhulikhel, Nepal); Partners Human Research
Committee (Boston, MA); the University Health Network
Research Ethics Board (Toronto, Canada); the Stanford
University Institutional Review Board (Stanford, CA); the
Ethical Review Committee of Aga Khan University (Karachi,

Table 1. Sentinel Healthcare Facilities, Study Period, Case Definitions, and Data Sources in Bangladesh, India, Nepal, and Pakistan, Surveillance for
Enteric Fever in Asia Project (SEAP) Phase I, 2012–2016
Country

Sentinel Healthcare Facilities

Study Period

Case Definitions

Data Sources

Bangladesh

Dhaka Shishu Hospital and Shishu Sasthya
Foundation Hospital, Dhaka

January 2013–
December 2014

Suspected case: a patient with a final
clinical diagnosis of enteric fever
without laboratory confirmation of
S. Typhi or S. Paratyphi infection
through blood culture;
Laboratory-confirmed case: a patient
with S. Typhi or S. Paratyphi isolated from the blood by culture

Laboratory and clinical records of hospitalized laboratory-confirmed cases

India

Postgraduate Institute of Medical Sciences, January 2014–
Chandigarh; Medanta Hospital, New
December 2015
Delhi; Apollo Hospital, Kolkata; Kasturba
Medical College – Manipal University
Hospital, Manipal and
Christian Medical College, Vellore

Laboratory-confirmed case: a patient
with S. Typhi or S. Paratyphi isolated from the blood by culture;
Surgical case: a patient with intestinal
perforation regardless of blood culture confirmation

Laboratory records of laboratory-confirmed cases and clinical records of
hospitalized laboratory-confirmed
cases and surgical cases

Nepal

Bayalpata Hospital, Achlam; Damauli
Hospital, Vyas; Dhulikhel Hospital,
Kavrepalanchowk; and Kirnetar Health
Center, Dolakha

August 2013–
June 2016

Suspected case: a patient
>12 months of age presenting to
the study sites with a self-reported
>72-hour history of fever;
Laboratory-confirmed case: a patient
with S. Typhi or S. Paratyphi isolated from blood by culture

Questionnaires administered to
participants, clinical records, and
laboratory records of suspect and
laboratory-confirmed cases

Pakistan

Aga Khan University Hospital and Aga
Khan Hospital for Women and Children,
Karachi; Aga Khan Hospital Hyderabad,
Hyderabad

January 2012–
December 2014

Laboratory-confirmed case: a patient
with S. Typhi or S. Paratyphi isolated from the blood by culture

Laboratory and clinical records of hospitalized laboratory-confirmed cases

Abbreviations: S. Paratyphi, Salmonella enterica subspecies enterica serovar Paratyphi; S. Typhi, Salmonella enterica subspecies enterica serovar Typhi.
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Ethical Review

Pakistan); and the Ethical Review Committee of Bangladesh
Institute of Child Health (Dhaka, Bangladesh).
Identifying personal information was accessible only to evaluation staff at the sites. All data reported to investigators were
deidentified.
RESULTS

DISCUSSION

This study generated data on enteric fever prevalence among
febrile patients, by age, sex, and time (month/year), along with
information on other clinical factors and antimicrobial resistance among hospitalized participants with enteric fever from
sentinel sites in 4 countries, allowing for cross-site comparison.
These results were critical to informing data collection for the
prospective phase of the SEAP. While prospective surveillance
will occur in India through a separate surveillance system (the
National Surveillance System for Enteric Fever in India), we
have identified sites in Bangladesh, Nepal, and Pakistan that
continue to experience a sustained burden of enteric fever and
are capable of contributing useful information on disease burden in prospective surveillance.
In Pakistan, S. Typhi infections were concentrated around
younger ages, and while Bangladesh had pediatric cases only,
because the sites were pediatric hospitals, nearly a quarter of
S. Typhi–infected participants were <2 years old. This is an
important observation, since these ages represent a population
that can be protected with TCVs if a vaccination program is
implemented. While overall the burden has shifted to an older

Table 2. Blood Culture Positivity Rate Among Individuals With Enteric Fever During Each Country-Specific Study Period, Bangladesh, India, Nepal, and
Pakistan, Surveillance for Enteric Fever in Asia Project (SEAP) Phase I, 2012–2016
Positive Blood Culture Results, No. (%)
Country

S. Typhi Detected

S. Paratyphi Detected

Overall

Bangladesh

24

15 917

241 (1.5)

38 (0.24)

279 (1.75)

India

24

267 536

1147 (0.43)

271 (0.1)

Nepal

34

87 (2)

22 (0.5)

Pakistan

36

1979 (1.49)

893 (0.67)

aData

Duration of Data Collection, Mo

Blood Cultures Performed, No.

4309a
133 017

1418 (0.53)
109 (2.5)
2872 (2.2)

are for participants enrolled in an ongoing prospective surveillance study, using a case definition of ≥3 days of fever.

Enteric Fever Surveillance in Asia • JID 2018:218 (Suppl 4) • S191
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Overall results from sites in each country, including the number of blood cultures and blood culture positivity rate (total
and by organism), are shown in Table 2 and described below.
At the Bangladesh hospitals, 51 923 children were admitted
to the site hospitals, and of those admitted, 15 917 (31%) had
blood cultures performed. Nearly 3% (443 of 15 917) were culture positive for significant bacterial growth, and 63% of these
isolates (279 of 443) were confirmed to be S. Typhi (241 [86%])
or S. Paratyphi (38 [14%]). An additional 1591 children were
suspected as having enteric fever, yielding 1870 children with
suspected or confirmed enteric fever. This represents 3.6% of
all hospital admissions (1870 of 51 923) in both hospitals in the
2-year period. At all 5 hospitals in India, 267 536 blood cultures
were performed during the study period, and of these, 1418
(0.53%) were positive for S. Typhi (1147 [81%]) or S. Paratyphi
(271 [19%]). In the 4 Nepal sites, 4309 participants were
enrolled as having suspected infection, of whom 176 (4.1%)
had a blood culture positive for pathogenic bacteria; 109 (62%;
2.5% of participants with blood cultures performed) had cultures positive for S. Typhi (87 [80%]) or S. Paratyphi (22 [20%]).
Among the 133 017 blood cultures performed in the hospitals in
Pakistan, 2872 (2.2%) were positive for S. Typhi (1979 [69%]) or
S. Paratyphi (893 [31%]).
The age distributions of participants with laboratory-confirmed cases varied between the 4 countries (see Figure 1).
Bangladesh had the youngest participants for both S. Typhi
(median, 3 years; interquartile range [IQR], 2–6 years) and
S. Paratyphi (3 years; IQR, 2–6 years) infection, but this was
expected as the 2 site hospitals served pediatric patients only.
In Pakistan, which also captured more pediatric cases, participants with S. Typhi infection were significantly younger, compared with S. Paratyphi–infected participants (median, 7 years
[IQR, 3–13 years] vs 15 years [IQR, 6–25 years]; P < .0001).
Nepal, however, had age distributions curves shifted toward
young adults (median, 19 years [IQR, 14–26 years] for S. Typhi

infection and 20 years [IQR, 17–24 years] for S. Paratyphi infection), as did India (median, 24 years [IQR, 14–28 years] for S.
Typhi infection and 24 years [IQR, 18–30 years] for S. Paratyphi
infection). The difference in ages between organisms was significant in India (P = .01) but not in Nepal. In all 4 countries, the
sex of the majority of the participants was male (68% in India,
61% in Pakistan, 55% in Bangladesh, and 52% in Nepal).
Antimicrobial resistance patterns for each country, by organism, are shown in Figure 2. Overall, a higher proportion of
S. Typhi isolates were resistant to chloramphenicol, ampicillin, and trimethoprim-sulfamethoxazole, compared with S.
Paratyphi isolates. A high proportion of both S. Typhi and S.
Paratyphi isolates from all 4 countries were nonsusceptible to
ciprofloxacin, and a number of isolates exhibited resistance to
ceftriaxone (1 of 115 S. Typhi isolates in Nepal and 4 of 418 in
India) and azithromycin (2 of 23 S. Paratyphi isolates in Nepal
and 2 of 30 S. Typhi isolates and 1 of 3 S. Paratyphi isolates in
India).
Complete results are available in the country-specific articles
published in this supplement [9, 12–14].
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Figure 1. Age distribution of enteric fever cases in Bangladesh (A), India (B), Pakistan (C), and Nepal (D), Surveillance for Enteric Fever in Asia Project (SEAP) Phase I,
2012–2016. S. Paratyphi, Salmonella enterica subspecies enterica serovar Paratyphi; S. Typhi, Salmonella enterica subspecies enterica serovar Typhi.

population in India and Nepal as compared to Pakistan and
Bangladesh, there remains a considerable burden of S. Typhi
at the younger ages and a need for TCV implementation; the
older population would also benefit from the WHO’s recommendation for a catch-up campaign beginning at 15 years [3].
These differences in ages should be viewed in the context of the
study design, though, because the differences could be partially
explained by trends in healthcare-seeking behavior. This is also
the case for sex distribution; literature has shown that generally a higher proportion of males seek care at the hospital, especially in younger ages [15]. Prospective surveillance performed
in these countries will allow us to adjust incidence estimates
based on reported care-seeking behavior and to estimate rates
of infection by sex and age group.
We were also able to review current patterns of antimicrobial
resistance in all 4 countries. There is still a high proportion of
S. Typhi isolates resistant to chloramphenicol, ampicillin, and
trimethoprim-sulfamethoxazole, especially in Pakistan and
Bangladesh [12, 14]. Since the proportion of isolates in these
S192 • JID 2018:218 (Suppl 4) • Barkume et al

countries that are nonsusceptible to ciprofloxacin is nearing
100%, this leaves third-generation cephalosporins, azithromycin, and carbapenems as the last remaining oral antibiotics for
treating typhoid. As we have identified a few isolates in Nepal
and India resistant to these agents [9, 13], continued close monitoring of antimicrobial resistance is essential to inform appropriate treatment recommendations.
SEAP Phase I has yielded valuable information on the enteric
fever burden across multiple settings in South Asia, but the
results are best considered in the context of the chosen study
settings. There may be an upward bias in incidence estimates
generated in urban populations when compared with rural populations, likely because of transmission drivers such as population density and scarce access to clean water and sanitation [16].
Indeed, data from the Nepal study described in this supplement
found that the prevalence of enteric fever among febrile individuals was strongly correlated with population density [9].
In addition to limitations in in-country generalizability
due to the selected sites, SEAP Phase I provides an important
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perspective on key issues and limitations of retrospective data.
Data obtained were limited in terms of comparability across
settings and period. The data from each setting were highly
variable with regard to availability, including variability for the
surveillance period, age groups included in surveillance, and
surveillance methods. Perhaps most significant was the variability in case definitions used for participants with suspected
cases for whom a blood culture was requested. The lack of standardized criteria for requesting blood culture makes the diagnosis of enteric fever highly subjective to the treating clinicians’
opinions. This is illustrated in Nepal, where half of individuals with a fever duration of >3 days were given a provisional
clinical diagnosis of typhoid, but fewer than 5% of these individuals had culture-confirmed infection [9]. Furthermore, clinicians in resource-poor settings may be less likely to prescribe
testing for poorer patients, who are possibly at a higher risk
of enteric fever and subsequent poor outcomes. Additionally,
hospital-based studies have an inherent limitation in that they
underestimate the disease burden in the community, owing to
differential health-seeking behaviors [17]. Active, community-based surveillance, is also more likely to be able to identify
complications and sequelae that occur in patients with typhoid

fever after discharge from a hospital or treatment at an outpatient clinic. These limitations and others [18], combined with
nonstandardized case definitions, have important implications
for disease burden and incidence estimations, which form
the basis of national and global policies [1, 2]. The data from
Phase I were also limited to what was available retrospectively
through existing data sources, primarily clinical records from
a few sites. While laboratory data were relatively more complete and available, linking laboratory and clinical data sources
presented difficulties. Clinical records were either missing or
did not adequately capture the required information for a large
proportion of laboratory-confirmed cases, specifically among
individuals seen in outpatient departments. This prohibited
sufficient characterization of the clinical profile of laboratory-confirmed cases and differences in clinical profiles by antimicrobial resistance. This is an especially critical lesson learned
in the era of rising antimicrobial resistance and a potentially
increased severity of illness associated with resistant strains
[19–21].
Phase II of the SEAP will address many of these limitations
inherent to retrospective study design. For example, the protocol for Phase II has a clearly defined study population, using
Enteric Fever Surveillance in Asia • JID 2018:218 (Suppl 4) • S193
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a created catchment area to define eligibility, and standardized
case definitions, which differ by enrollment location within the
hospital (eg, outpatient, inpatient, and surgical settings). We
also plan to prospectively collect robust data through multiple
sources, including patient interviews, laboratory records, and
medical charts, to improve the quality and amount of available information and its potential to be appropriately linked
and analyzed. Unlike Phase I, Phase II will be able to estimate
incidence on the basis of data from hospital-based surveillance,
using the low-cost hybrid method outlined by Luby et al [17].
We plan to obtain the proportion of participants with disease
matching our case definition who sought healthcare and create
age-stratified incidence by using healthcare-seeking behavior,
as well as to adjust for a variety of factors related to potential
biases as described by another article in this supplement [22], to
deliver more-discrete and accurate estimates to country governments and decision makers.
SEAP Phase I is one of the few multicenter studies in South
Asia that have attempted to retrospectively assess the enteric
fever burden by using existing clinical and disease surveillance
systems. With investment in capacity building, SEAP is building a low-cost and sustainable surveillance system that can be
leveraged for ongoing surveillance to evaluate the impact of
interventions, including vaccines, by integrating data capture
into existing site infrastructure. It is unlikely that vaccines will
entirely eliminate typhoid, shown by modeling in South Asia,
but that a combination of water, sanitation, and hand hygiene
interventions and vaccination may eliminate typhoid in settings where it is endemic [23]. Since the recent availability of
a licensed and WHO-prequalified typhoid conjugate vaccine
(Typbar-TCV; Bharat Biotech, India), which has been shown
to be immunogenic in children aged <2 years, demonstrating
vaccine effectiveness and public health impact is more important than ever [5, 24–26]. SEAP Phase II will produce not only
accurate estimates of the burden of disease in selected areas
in Bangladesh, Nepal, and Pakistan, but also baseline data
for future vaccine effectiveness studies in the site catchment
areas, as well as evaluate the impact of additional long-term
interventions, such as improvements in water and sanitation
infrastructure.

